Filing summary: AcelRx Pharmaceuticals, Inc. 10-Q, Q1 2016
Entity note: The supplied filing is for AcelRx Pharmaceuticals, Inc., not TALPHERA, INC. It covers the quarter ended March 31, 2016 and was signed May 2, 2016.
Business context
AcelRx is a development-stage specialty pharmaceutical company focused on acute-pain therapies. Its lead programs are investigational ARX-04 and Zalviso. Zalviso was approved in Europe in September 2015 and is commercialized there by partner Grünenthal; U.S. FDA approval remained outstanding for both programs.
Financial performance and position
Amounts below are in millions of dollars except per-share data. The income and cash-flow comparisons are Q1 2016 versus Q1 2015; balance-sheet comparisons are March 31, 2016 versus December 31, 2015.
| Metric | Q1 2016 / March 31, 2016 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $3.025 | $0.181 |
| Operating costs and expenses | $11.547 | $11.581 |
| Operating loss | $(8.522) | $(11.400) |
| Net loss | $(10.981) | $(10.026) |
| Basic / diluted loss per share | $(0.24) / $(0.25) | $(0.23) / $(0.27) |
| Cash used in operating activities | $(6.229) | $(10.749) |
| Cash, cash equivalents and investments | $107.157 | $113.464 |
| Total assets | $121.225 | $127.785 |
| Total liabilities | $97.782 | $94.672 |
| Hercules debt balance | $21.1 | $20.9 |
| Liability for sold future royalties | $65.8 | $63.6 |
Q1 revenue comprised $1.793 million of Grünenthal collaboration revenue and $1.232 million of DoD contract revenue. Collaboration revenue included $1.4 million for commercial inventory delivered to Grünenthal; the filing says Zalviso’s first commercial sale occurred in April, so no royalty revenue was recognized in Q1. Cost of goods sold was $3.599 million, exceeding reported revenue; the filing does not provide a consolidated gross-margin measure.
Research and development expense fell 34% to $4.171 million, and general and administrative expense fell 16% to $3.777 million. Operating loss narrowed, but net loss increased, chiefly reflecting $2.196 million of non-cash imputed interest on the royalty-monetization liability and lower other income from warrant revaluation. Operating cash use declined year over year. Cash and investments decreased $6.3 million from year-end; cash alone declined $2.5 million during the quarter.
Current assets were $112.794 million and current liabilities $16.804 million at quarter-end. The Hercules loan is secured by substantially all assets other than intellectual property and assets sold in the royalty monetization; it matures in 2017. The royalty-sale liability is a debt-like accounting obligation, not ordinary funded loan principal: AcelRx received $65 million gross ($61.2 million net) from PDL, which receives specified royalties and milestones up to a $195 million cap. The company estimates an approximately 14% effective annual interest rate on this liability.
Material changes and developments
- Revenue rose from $0.181 million to $3.025 million, reflecting DoD reimbursement and commercial-preparation supply deliveries; it did not represent established recurring product sales.
- R&D and G&A costs declined following the 2015 cost-reduction plan, while cost of goods sold rose with Zalviso commercial production and delivery.
- ARX-04’s Phase 3 program expanded by approximately 160 patients after FDA feedback. SAP302’s extension and SAP303 began in March 2016.
- The DoD amended its contract to support the added ARX-04 enrollment and SAP303, extending performance through March 9, 2017 without increasing the contract’s stated value of up to $17 million.
- The interest-only period on Hercules debt was extended through September 30, 2016 after conditions were met. The third loan tranche was unavailable because Zalviso did not receive U.S. FDA approval by the required date.
- A securities class action concerning Zalviso-related statements was dismissed with prejudice in January 2016.
Outlook, commentary and risks
- Management expected existing capital resources to fund operations through at least the first half of 2017, but said resources would not fund operations until self-sustaining revenue. The estimate is subject to trial scope, regulatory requirements and other uncertainties.
- AcelRx anticipated an ARX-04 NDA submission in Q4 2016 and an EU marketing application in the first half of 2017. SAP302 was expected to complete by Q3 2016. These are forward-looking targets, not guarantees.
- Grünenthal made Zalviso’s first commercial sale in April 2016 and planned a limited German hospital pilot before broader rollout, conditional on pilot success. AcelRx expected 2016 royalty revenue to be minimal.
- Zalviso’s U.S. NDA remained subject to an FDA Complete Response Letter and a required additional clinical study, IAP312. Its start was postponed pending supply production/testing and site readiness; AcelRx warned that inability to begin before year-end could jeopardize its ability to complete the study and resubmit.
- Key risks include clinical or regulatory delay or failure, additional trial requirements and resulting funding needs, uncertain European uptake and reimbursement, reliance on Grünenthal and contract manufacturers, limited qualified supply sources, and the possibility of needing additional capital on unfavorable terms or not at all.
- Management estimated a further $7.1 million of non-cash royalty-monetization interest expense in 2016, bringing the estimated 2016 total to $9.3 million; the estimate may change with royalty expectations and timing.
- Management concluded disclosure controls were effective as of quarter-end and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the intended issuer: this source is AcelRx’s filing, not a TALPHERA, INC. filing.
- Check whether ARX-04 studies completed on schedule and whether the FDA accepted the planned NDA scope and timing.
- Track IAP312 initiation, completion, results and the requirements for Zalviso NDA resubmission.
- Assess the German Zalviso pilot, broader commercialization, sales and resulting royalties after PDL’s share.
- Reconcile cash burn and runway against the stated first-half-2017 funding horizon, trial costs and Hercules repayment schedule.
- Review the assumptions behind the $65.8 million royalty-sale liability and its imputed interest, as well as the remaining milestones and cash flows retained by AcelRx.